HER2 Intermediate Breast Cancers.
Jensen
Kristin C
KC
Nielsen
Torsten O
TO
Gilks
C Blake
CB
West
Robert B
RB
D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D018628:Gene Dosage; D017408:Guidelines as Topic; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000037:antagonists & inhibitors; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human